Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates

Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant...

Related Keywords

Boston ,Massachusetts ,United States ,Amanda Cray ,Dmitri Bobilev ,John Valliant ,Safety Review Committee ,Mcmaster University ,Investor Relations Corporate Communications ,Astrazeneca ,Nasdaq ,Exchange Commission ,Fusion Pharmaceuticals ,Fusion Pharmaceuticals Inc ,Niowave Inc ,Prnewswire Fusion Pharmaceuticals Inc ,Drug Administration ,Development Plan ,Interim Phase ,Chief Executive Officer John Valliant ,Chief Medical Officer ,Response Inhibitors ,Good Manufacturing Practice ,Private Securities Litigation Reform Act ,Investor Relations ,Biotechnology ,Computer Amp Electronics ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,New Products Amp Services ,Clinical Trials Amp Medical Discoveries ,